Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.
The purpose of this study was to evaluate the pharmacokinetics of amphotericin B colloidal dispersion and its effect on creatinine clearance in bone marrow transplant patients with systemic fungal infections. Seventy-five patients (42 females and 33 males) with a median age of 34.5 years and a median weight of 70.0 kg were enrolled in the study. Patients received 1 of 15 dose levels (range, 0.5 to 8.0 mg/kg of body weight) daily for a mean duration of 28 days and a mean cumulative dose amount of 8 g. Plasma samples for amphotericin B determination (median number, 4; range, 2 to 30) and daily serum creatinine values were obtained for each patient. Iterative two-stage analysis, one of several approaches to population pharmacokinetic and pharmacodynamic modelling, was employed for the pharmacokinetic analysis. The plasma data were available for 51 of 75 patients and were best described by a two-compartment model. Both plasma clearance and volume of distribution increased with escalating doses; the overall average terminal elimination half-life was 29 h. Of the covariates studied, only body weight and dose size were significant. Serum creatinine values over the duration of therapy were available for 59 of 75 patients. Overall, there was no net change in renal function over the duration of therapy; 12 patients had > 30% increases in creatinine clearance, whereas 13 had > 30% decreases. No measure of amphotericin B colloidal dispersion exposure, demographic values, or concomitant treatment with other medications was related to changes in the creatinine clearance.
Amantea
M A
MA
SEQUUS Pharmaceuticals, Inc., Menlo Park, California 94025, USA.
Bowden
R A
RA
Forrest
A
A
Working
P K
PK
Newman
M S
MS
Mamelok
R D
RD
D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000502:physiology*; D002648:Child; D003401:Creatine / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000378:metabolism; D011153:Population
D000935:Antifungal Agents; D000666:Amphotericin B; D003401:Creatine